Literature DB >> 23801638

Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database.

Vincent Lo Re1, Kevin Haynes, David Goldberg, Kimberly A Forde, Dena M Carbonari, Kimberly B F Leidl, Sean Hennessy, K Rajender Reddy, Pamala A Pawloski, Gregory W Daniel, T Craig Cheetham, Aarthi Iyer, Kara O Coughlin, Sengwee Toh, Denise M Boudreau, Nandini Selvam, William O Cooper, Mano S Selvan, Jeffrey J VanWormer, Mark I Avigan, Monika Houstoun, Gwen L Zornberg, Judith A Racoosin, Azadeh Shoaibi.   

Abstract

PURPOSE: The validity of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify diagnoses of severe acute liver injury (SALI) is not well known. We examined the positive predictive values (PPVs) of hospital ICD-9-CM diagnoses in identifying SALI among health plan members in the Mini-Sentinel Distributed Database (MSDD) for patients without liver/biliary disease and for those with chronic liver disease (CLD).
METHODS: We selected random samples of members (149 without liver/biliary disease; 75 with CLD) with a principal hospital diagnosis suggestive of SALI (ICD-9-CM 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) in the MSDD (2009-2010). Medical records were reviewed by hepatologists to confirm SALI events. PPVs of codes and code combinations for confirmed SALI were determined by CLD status.
RESULTS: Among 105 members with available records and no liver/biliary disease, SALI was confirmed in 26 (PPV, 24.7%; 95%CI, 16.9-34.1%). Combined hospital diagnoses of acute hepatic necrosis (570) and liver disease sequelae (572.8) had high PPV (100%; 95%CI, 59.0-100%) and identified 7/26 (26.9%) events. Among 46 CLD members with available records, SALI was confirmed in 19 (PPV, 41.3%; 95%CI, 27.0-56.8%). Acute hepatic necrosis (570) or hepatorenal syndrome (572.4) plus any other SALI code had a PPV of 83.3% (95%CI, 51.6-97.9%) and identified 10/19 (52.6%) events.
CONCLUSIONS: Most individual hospital ICD-9-CM diagnoses had low PPV for confirmed SALI events. Select code combinations had high PPV but did not capture all events.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ICD-9 codes; hepatotoxicity; liver injury; pharmacoepidemiology; validity

Mesh:

Year:  2013        PMID: 23801638      PMCID: PMC4409951          DOI: 10.1002/pds.3470

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  22 in total

1.  Safety of newly approved drugs: implications for prescribing.

Authors:  Robert J Temple; Martin H Himmel
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

Review 2.  Drug-induced hepatotoxicity.

Authors:  William M Lee
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 3.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

5.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

Authors:  Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 6.  Terbinafine hepatotoxicity: case report and review of the literature.

Authors:  N F Fernandes; S A Geller; T L Fong
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

Review 7.  Classification, etiology, and considerations of outcome in acute liver failure.

Authors:  R Williams
Journal:  Semin Liver Dis       Date:  1996-11       Impact factor: 6.115

8.  Outcome and prognostic markers in severe drug-induced liver disease.

Authors:  Einar Björnsson; Rolf Olsson
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

9.  Differences between clinical trials and postmarketing use.

Authors:  Karin Martin; Bernard Bégaud; Philippe Latry; Ghada Miremont-Salamé; Annie Fourrier; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 10.  Acute liver failure in the United States.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2003-08       Impact factor: 6.115

View more
  32 in total

1.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

2.  Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.

Authors:  Vibha C A Desai; Scott C Quinlan; Anne C Deitz; Jinghua He; Crystal N Holick; Stephan Lanes
Journal:  J Neurooncol       Date:  2017-07-17       Impact factor: 4.130

3.  Ascertainment of acute liver injury in two European primary care databases.

Authors:  A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

4.  Comment on: "Desideratum for evidence-based epidemiology".

Authors:  Sean Hennessy; Charles E Leonard
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

5.  Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.

Authors:  Monica L Schmidt; A Sidney Barritt; Eric S Orman; Paul H Hayashi
Journal:  Gastroenterology       Date:  2015-01-23       Impact factor: 22.682

6.  Evaluation of Use of Technologies to Facilitate Medical Chart Review.

Authors:  Loreen Straub; Joshua J Gagne; Judith C Maro; Michael D Nguyen; Nicolas Beaulieu; Jeffrey S Brown; Adee Kennedy; Margaret Johnson; Adam Wright; Li Zhou; Shirley V Wang
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

7.  Patients With Persistently Low MELD-Na Scores Continue to Be at Risk of Liver-related Death.

Authors:  Nikhilesh R Mazumder; Kofi Atiemo; Amna Daud; Abel Kho; Michael Abecassis; Josh Levitsky; Daniela P Ladner
Journal:  Transplantation       Date:  2020-07       Impact factor: 4.939

8.  Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events.

Authors:  Vincent Lo Re; Dena M Carbonari; Kimberly A Forde; David Goldberg; James D Lewis; Kevin Haynes; Kimberly B F Leidl; Rajender K Reddy; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-10       Impact factor: 2.890

9.  Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.

Authors:  Vincent Lo Re; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Kevin Haynes; Jason A Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley
Journal:  Am J Med       Date:  2015-11-17       Impact factor: 4.965

10.  Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods.

Authors:  Rachel L Richesson; Jimeng Sun; Jyotishman Pathak; Abel N Kho; Joshua C Denny
Journal:  Artif Intell Med       Date:  2016-06-25       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.